Fig 1: Overall survival analysis in luminal B HER2+ breast cancer. HNMT, Histamine N-Methyltransferase; HRH1, Histamine Receptor H1; HRH2, Histamine Receptor H2; HRH3, Histamine Receptor H3; HRH4, Histamine Receptor H4; DRD1, Dopamine Receptor D1; DRD2, Dopamine Receptor D2; DRD3, Dopamine Receptor D3; DRD4, Dopamine Receptor D4; DRD5, Dopamine Receptor D5; EGR1, Early Growth Response 1; ICAM1, Intercellular Adhesion Molecule 1; MAPK9, Mitogen-Activated Protein Kinase 9 (JNK2); OXT, Oxytocin/Neurophysin I Prepropeptide; SIRT4, Sirtuin 4
Fig 2: Overall survival analysis in luminal B HER2− breast cancer. HNMT, Histamine N-Methyltransferase; HRH1, Histamine Receptor H1; HRH2, Histamine Receptor H2; HRH3, Histamine Receptor H3; HRH4, Histamine Receptor H4; DRD1, Dopamine Receptor D1; DRD2, Dopamine Receptor D2; DRD3, Dopamine Receptor D3; DRD4, Dopamine Receptor D4; DRD5, Dopamine Receptor D5; EGR1, Early Growth Response 1; ICAM1, Intercellular Adhesion Molecule 1; MAPK9, Mitogen-Activated Protein Kinase 9 (JNK2); OXT, Oxytocin/Neurophysin I Prepropeptide; SIRT4, Sirtuin 4
Fig 3: Venn diagram showing genes differentiating breast cancer from the control in microarray experiment. HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; C, control; HNMT, Histamine N-Methyltransferase; HRH1, Histamine Receptor H1; HRH2, Histamine Receptor H2; HRH3, Histamine Receptor H3; HRH4, Histamine Receptor H4; DRD1, Dopamine Receptor D1; DRD2, Dopamine Receptor D2; DRD3, Dopamine Receptor D3; DRD4, Dopamine Receptor D4; DRD5, Dopamine Receptor D5; EGR1, Early Growth Response 1; ICAM1, Intercellular Adhesion Molecule 1; MAPK9, Mitogen-Activated Protein Kinase 9 (JNK2); OXT, Oxytocin/Neurophysin I Prepropeptide; SIRT4, Sirtuin 4
Fig 4: Interaction Network of Selected BAs-related Genes Generated Using the STRING Database. HNMT, Histamine N-Methyltransferase; HRH1, Histamine Receptor H1; HRH2, Histamine Receptor H2; HRH3, Histamine Receptor H3; HRH4, Histamine Receptor H4; DRD1, Dopamine Receptor D1; DRD2, Dopamine Receptor D2; DRD3, Dopamine Receptor D3; DRD4, Dopamine Receptor D4; DRD5, Dopamine Receptor D5; EGR1, Early Growth Response 1; ICAM1, Intercellular Adhesion Molecule 1; MAPK9, Mitogen-Activated Protein Kinase 9 (JNK2); OXT, Oxytocin/Neurophysin I Prepropeptide; SIRT4, Sirtuin 4
Fig 5: Overall survival analysis in luminal A breast cancer. HNMT, Histamine N-Methyltransferase; HRH1, Histamine Receptor H1; HRH2, Histamine Receptor H2; HRH3, Histamine Receptor H3; HRH4, Histamine Receptor H4; DRD1, Dopamine Receptor D1; DRD2, Dopamine Receptor D2; DRD3, Dopamine Receptor D3; DRD4, Dopamine Receptor D4; DRD5, Dopamine Receptor D5; EGR1, Early Growth Response 1; ICAM1, Intercellular Adhesion Molecule 1; MAPK9, Mitogen-Activated Protein Kinase 9 (JNK2); OXT, Oxytocin/Neurophysin I Prepropeptide; SIRT4, Sirtuin 4
Supplier Page from MyBioSource.com for Human Dopamine D1 receptor ELISA Kit